Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,460 | In Stock | |
50 mg | $1,970 | In Stock |
Description | Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma. |
In vivo | Methods: Anrukinzumab (10 mg/kg, intravenous injection, single dose) was used to treat adult male cynomolgus monkeys with lung inflammation to observe its therapeutic effect. Results: Anrukinzumab was able to reduce the total cell count, eosinophil count, and neutrophil count in bronchoalveolar lavage (BAL) fluid. [1] |
Synonyms | IMA-638 |
Cas No. | 910649-32-0 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.